The regulatory effect of lncRNA LINC00943 on the progression of hepatocellular carcinoma and its relationship with clinicopathological features - 07/02/24
Highlights |
• | LncRNA LINC00943 has the potential to become a prognostic biomarker for HCC. |
• | LncRNA LINC00943 was highly expressed in HCC tissues and cell specimens. |
• | LncRNA LINC00943 was associated with TNM stage and lymph node metastasis of HCC. |
• | LncRNA LINC00943 sponge miR-195–5p suppressed the biological activity of HCC cells. |
Abstract |
Background |
The risk factors for the pathogenesis of HCC are highly variable, and the prognosis of patients is very unsatisfactory. In this study, we investigated the regulatory effect of LINC00943 on HCC progression and its relationship with clinicopathological features.
Methods |
LINC00943 level in HCC tissues and cell specimens was verified by RT-qPCR. The pathologic significance of LINC00943 in the prognosis of HCC was analyzed by Kaplan-Meier and Cox regression analyses. The behavioral function of LINC00943 in HCC cells was evaluated via CCK-8 and Transwell assays. The specific targeting relationship between LINC00943 and miR-195–5p was investigated by luciferase activity assay.
Results |
LINC00943 was highly expressed in HCC tissues and cell specimens. Clinical data analysis showed that elevated LINC00943 indicated poor prognosis in patients with HCC and was related to TNM stage and lymph node metastasis. Cell experiments demonstrated that silencing LINC00943 sponge miR-195–5p suppressed the proliferation, migration and invasion of HCC cells. Mechanistically, miR-195–5p inhibitor remedied the suppressive effect of silencing LINC00943 on the biological functions of HCC cells.
Conclusion |
LINC00943 may be an independent prognostic factor of HCC, which provides new thinking for the prognosis and treatment of HCC patients.
Il testo completo di questo articolo è disponibile in PDF.Keywords : HCC, LINC00943, miR-195–5p, Prognosis, Clinical features
Mappa
Vol 48 - N° 2
Articolo 102273- Febbraio 2024 Ritorno al numero
Articolo precedente
- Sustained response and HBsAg loss after nucleo(s)tide analogue discontinuation in chronic hepatitis B patients: the prospective SNAP study
- Sylvia M. Brakenhoff, Mark Claassen, Pieter Honkoop, Robert J. de Knegt, Annemiek A. van der Eijk, André Boonstra, Robert A. de Man, Milan J. Sonneveld
- Enhanced therapeutic outcomes with atezolizumab-bevacizumab and SIRT combination compared to SIRT alone in unresectable HCC: A promising approach for improved survival
- Amel Mejait, Charles Roux, Marine Soret, Edouard Larrey, Mathilde Wagner, Jean Charles Bijot, Charlotte Lussey-Lepoutre, Dominique Thabut, Claire Goumard, Philippe Maksud, Manon Allaire
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?